Algernon Pharmaceuticals Inc (AGNPF)

[Money $hot]

At long last, through all the smoke and fire, pain and suffering, blood and guts, I've clearly and convincingly found my exit out of Dante's Inferno (Algernon Pharmaceuticals Inc.). It's been documented here in plain and EZ to understand English. There is no doubt the masses of AGNPF shareholders entered through the doors of purgatory and found themselves fighting like hell. Whatever level of the journey shareholders find themselves in, I hope one day they too will find their peace.

I Have

Have @ It

M$


The Inferno PostScript

Christopher Moreau has controlled the direction of Algernon Pharmaceuticals since Q1 2018. The company purchased a repurposed drugs strategy from Nash Pharmaceuticals in Q4 2018. Of the four leading compounds purchased by Algernon, only one of those drugs have been advanced into a so-called Phase 2 study. The business strategy that you were sold underhandedly led you to believe they could run expeditious Phase 2 studies that would immediately move to Phase 3 given a successful data readout. However, that is not what you were truly sold. The truth is Algernon runs cheap studies in countries outside of North America that are not designed to move beyond Phase 2. Their business model actually requires at minimum twice as many years at Phase 2 than many other biotech companies. IMO, shareholders continue to endure a long drawn out and underhanded scam since becoming Algernon Pharmaceuticals in 2018. In summary, Algernon Pharmaceuticals has taken nearly 4 years to run a study on just one of its originally intended disease targets. It won't be until Q4 2022 or Q1 2023 before you receive a Final Data Readout for IPF/Chronic Cough (an ultra low budget 20 patient study). Algernon has not pursued their repurposed NASH or IBD drugs since their purchase from Nash Pharmaceuticals in 2018. Each being 30% of the overall cost to acquire such drugs. Algernon has only recently decided to pursue CKD with NP-251 (Repirinast), a drug tested preclinical back in 2019.CKD was also 30% of the overall cost to acquire such drugs, which required a 2 to 1 reverse split and subsequent doubling of shares thereafter (dilution on steroids). Sound familiar? Go figure. NP-251 was a Phase 2 entry level drug that is now a Phase 1 entry level drug.

Adding insult to injury, your management team has thrown out the speedy Phase 2 scam and reverted backwards to Phase 1 studies for all drugs in the pipeline. The company has moved backwards. Any claims to start from preclinical advancing directly to Phase 2 clinical trials is now a false and misleading statement. However, don't let that stop Algernon from still claiming it with pipeline graphics and other such ill literature. By the time Algernon Pharmaceuticals ever gets to its very 1st Randomized Double Blind Placebo Controlled Study Powered For Statistical Significance (THE GOLD STANDARD), it will be the year 2025 if you're lucky with Schleprock as your CEO. That's a 7 Year bad luck timeline to get real world data that will determine if your 1st leading compound will make it to a Phase 3 clinical trial. Christopher Moreau peddled the story of you having a 65% chance of success at Phase 2 to move to Phase 3 with both the COVID-19 study and pending IPF/Chronic Cough results. Moreau said that knowing neither of those studies were powered for statistical significance. Meaning, neither of those studied had/have a chance of advancing to Phase 3. You have been royally duped by management. It's incredible the company has not been sued by now. See the list of companies at the following link who ran clinical trials during Algernon's disastrous IPF/Chronic study in Australia.

pact.lungfoundation.com.au/find-a-trial/

You can see Algernon sticking out like a sore thumb when it comes to the Gold Standard for clinical trials. Algernon is a low rank company that peddles cheap penny stock shares and warrants to support insider lifestyles. No more. No less. No foreseeable changes in the future.

Of Note: Christopher Moreau told shareholders in at least one of those scripted webcasts where he spoke to people at other biotech companies and told them he could run Phase 2 studies on the cheap. None of those other biotech companies believed a word that he said. It’s most likely because Christopher Moreau was not talking about running Gold Standard studies like they were. Christopher Moreau was talking in another language. He was talking about running straight up BS studies that merely continue to waste shareholders' valuable time and money before ever running a straight forward clinical trial at Phase 2. You are screwed for at least the next 5 years if Algernon does not pivot ASAP to directly running a Gold Standard Phase 2 study in North America for Chronic Cough. That’s your only reasonable chance at the bogus “65% chance of success” spouted out of the mouth’s of Christopher Moreau (CEO) and Dr. Mark Williams (CSO) .

Schleprock @ The Helm of Algernon Pharmaceuticals Inc.




PostScript II

The Days Of Naivete 5+ Years Ago @ Breathtec Biomedical Inc.

/investorshub.advfn.com/boards/read_msg.aspx?message_id=129824673&txt2find=world